For the first time, researchers have identified a drug combination that enhances the brain's built-in waste-removal system, clearing the toxic proteins linked to Alzheimer's disease more effectively than a placebo. The findings, reported by New Scientist, suggest the treatment could delay the disease's onset by roughly seven years — a potentially transformative outcome for millions at risk.
The brain disposes of metabolic waste through the glymphatic system, a network of channels surrounding blood vessels that flushes debris into the lymphatic system and eventually the bloodstream. This system works hardest during deep sleep, when slow brain waves help propel waste fluid. But it deteriorates with age and declines sharply in people with Alzheimer's.
The new approach combines dexmedetomidine, a sedative already used in medical procedures, with midodrine, a drug that counteracts the sedative's tendency to lower blood pressure. Together, the pair — dubbed ACX-02 by developer Applied Cognition — was tested on 19 adults averaging 60 years old. After a night of sleep deprivation, participants napped for four hours while receiving the drug infusion. Blood samples taken before and after showed that ACX-02 cleared two types of amyloid and tau proteins significantly better than a placebo session conducted weeks later.
"This is a significant step forward," said Shiju Gu at Harvard University, who was not involved in the study. "It could benefit people with neurodegenerative disease, but even for healthy people, maybe you could use it to maximise the function of the brain."
Earlier mouse studies had already shown that dexmedetomidine boosted the deep brain waves responsible for driving waste clearance. In rodent models of Alzheimer's, the drug improved waste removal and slowed cognitive decline. The human trial led by Paul Dagum at Applied Cognition now provides the first evidence that the same mechanism can be harnessed in people.
The researchers estimate that if ACX-02's protein-clearing effect were sustained over several years, it could push back the onset or progression of Alzheimer's by about seven years, based on typical levels of misfolded amyloid seen in people who eventually develop the condition. While the study was small and short-term, the results open a promising new front in the fight against neurodegeneration — one that works with the brain's own housekeeping rather than against the disease directly.
